Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025;Cohort B results from the ASCEND trial accepted for an oral presentation at ESMO-GI 2025 Cash runway extending into the third quarter of 2026 with no debt Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatm ...

Core Insights - ARKO Corp. reported a net loss of $12.7 million for Q1 2025, a significant increase from a net loss of $0.6 million in the same quarter last year, indicating challenges in the current consumer environment [6][5] - The company achieved an adjusted EBITDA of $30.9 million, down from $33.2 million year-over-year, reflecting ongoing macroeconomic pressures [6][5] - Merchandise margin improved to 33.2% from 32.5%, despite a decline in merchandise contribution to $117.6 million from $134.9 million, primarily due to the dealerization program [6][10] - Retail fuel margin increased to 37.9 cents per gallon, up from 36.4 cents per gallon, although retail fuel contribution decreased to $85.3 million from $92.9 million [6][11] Financial Performance - Total revenues for Q1 2025 were $1.83 billion, down from $2.07 billion in Q1 2024, driven by a decrease in fuel revenue to $1.45 billion from $1.63 billion [38] - Fuel gallons sold decreased to 225,063 thousand gallons from 255,464 thousand gallons, with same-store fuel gallons sold down 6.2% [8][11] - Merchandise revenue also declined to $354.5 million from $414.7 million, with same-store merchandise sales decreasing by 6.9% [8][10] Strategic Initiatives - The company converted 59 retail stores to dealer sites in Q1 2025, with plans for further conversions throughout the year, expecting a cumulative annualized operating income benefit exceeding $20 million [6][5] - ARKO initiated a store remodeling initiative aimed at enhancing customer experience, with the first pilot remodel expected to begin construction in May 2025 [6][5] - The company launched the "Fueling America's Future" campaign, offering loyalty customers value promotions and discounts at the pump [6][5] Shareholder Returns - The Board declared a quarterly dividend of $0.03 per share, to be paid on May 30, 2025, reflecting confidence in cash generation capabilities [21][22] - During Q1 2025, the company repurchased approximately 1.3 million shares for about $5.2 million, indicating a commitment to shareholder returns [7][22] Liquidity and Capital Expenditures - As of March 31, 2025, ARKO's total liquidity was approximately $847 million, with $265 million in cash and cash equivalents and $582 million available under lines of credit [20] - Capital expenditures for the quarter were approximately $27.4 million, including investments in new stores and upgrades [20]

Delivers First Quarter Results in Line with and Above Guidance Ranges Reiterates Full Year 2025 Outlook and Provides Second Quarter 2025 Guidance SAN FRANCISCO, May 08, 2025 (GLOBE NEWSWIRE) -- Allbirds, Inc. (NASDAQ: BIRD), a global lifestyle brand that innovates with sustainable materials to make better products in a better way, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 Overview First quarter net revenue of $32.1 million, within the Company’s guidance range, ...

Core Insights - BioLife Solutions, Inc. reported a strong start to 2025 with a 33% year-over-year growth in cell processing revenue, reaching $21.6 million [1][2] - The company achieved a GAAP gross margin of 63% and a non-GAAP adjusted gross margin of 66% for Q1 2025, consistent with the same period in 2024 [5] - The net loss from continuing operations was reduced to $0.4 million in Q1 2025, compared to $3.2 million in Q1 2024, indicating improved financial performance [10][11] Financial Performance - Total revenue for Q1 2025 was $23.9 million, a 30% increase from $18.4 million in Q1 2024 [8] - Adjusted EBITDA for Q1 2025 was $5.7 million, representing 24% of revenue, up from $2.6 million or 14% of revenue in Q1 2024 [12] - The operating loss from continuing operations decreased to $1.2 million in Q1 2025 from $3.3 million in Q1 2024 [6][29] Business Highlights - The company processed 13 new U.S. FDA Master File cross references for its biopreservation media, bringing the total to 782 [7] - BioLife's biopreservation media is now embedded in 17 unique commercial cell and gene therapies, with expectations for further approvals and geographic expansions [7] - The acquisition of PanTHERA CryoSolutions was completed on April 4, 2025, enhancing BioLife's capabilities in the biopreservation market [7] Guidance and Outlook - BioLife Solutions affirmed its 2025 revenue guidance of $95.5 million to $99.0 million, reflecting a growth of 16% to 20% compared to 2024 [13] - The company anticipates maintaining gross margins in the low 60% range and adjusted gross margins in the mid-60% range for 2025 [13]

Core Insights - Nanox Imaging Ltd will report its financial results for Q1 2025 on May 22, 2025, before market open [1] - The conference call to discuss these results will be hosted by CEO Erez Meltzer and CFO Ran Daniel at 8:30 a.m. ET [1] Company Overview - Nanox is focused on transitioning to preventive healthcare through affordable medical imaging technologies utilizing advanced AI and proprietary digital X-ray sources [3] - The company's vision includes expanding its technology's reach beyond hospital settings, providing a comprehensive solution from scan to diagnosis, and leveraging AI for improved diagnostic accuracy [4] Product Ecosystem - Nanox.ARC is a multi-source digital tomosynthesis system designed to be cost-effective and user-friendly [4] - Nanox.AI LTD offers an AI-based suite of algorithms that enhance routine CT imaging readings to detect early signs of chronic diseases [4] - Nanox.CLOUD is a cloud-based platform for managing data from Nanox devices and providing tools for in-depth imaging analysis [4] - Nanox.MARKETPLACE is a decentralized marketplace providing remote access to radiology and cardiology experts, along with teleradiology services [4]

Financial Performance - Total revenues for Q1 2025 were $47.8 million, a decrease from $50.1 million in Q4 2024 but an increase from $41.3 million in Q1 2024 [3] - Analytics revenue for Q1 2025 was $42.5 million, down from $47.9 million in Q4 2024 but up from $38.5 million in Q1 2024 [3] - Integrated Yield Ramp revenue for Q1 2025 was $5.3 million, compared to $2.2 million in Q4 2024 and $2.8 million in Q1 2024 [3] Profitability Metrics - GAAP gross margin for Q1 2025 was 73%, up from 68% in Q4 2024 and 67% in Q1 2024 [4] - Non-GAAP gross margin for Q1 2025 was 77%, compared to 72% in both Q4 2024 and Q1 2024 [4] - GAAP net loss for Q1 2025 was $3.0 million, or ($0.08) per diluted share, compared to net income of $0.5 million, or $0.01 per diluted share in Q4 2024 [5] - Non-GAAP net income for Q1 2025 was $8.1 million, or $0.21 per diluted share, down from $9.9 million, or $0.25 per diluted share in Q4 2024 [6] Strategic Developments - The company experienced strong customer activity and platform development, driven by AI-driven digitization [7] - The acquisition of SecureWise was completed to enhance supply chain collaboration [10] - The company reaffirmed its annual revenue growth guidance of 21-23% for 2025 [7] Backlog and Financial Position - The backlog as of March 31, 2025, was $226.7 million [10] - Total assets increased to $389.972 million as of March 31, 2025, from $315.289 million at the end of 2024 [17][18]

First quarter revenue of $1.015 billion, up 3% year-over-year and up 4% when adjusted for foreign exchange*Security and cloud computing revenue represented 69% of total revenue in the first quarter and combined grew 10% year-over-year and 11% when adjusted for foreign exchange*GAAP net income per diluted share of $0.82, down 26% year-over-year and down 23% when adjusted for foreign exchange*, and non-GAAP net income per diluted share* of $1.70, up 4% year-over-year and up 6% when adjusted for foreign exchan ...

Financial Performance - Collegium Pharmaceutical reported Q1 2025 net revenue of $177.8 million, representing a 23% increase year-over-year from $144.9 million in Q1 2024 [9][24] - The company generated $149.2 million from its pain portfolio, up 3% year-over-year, with all three core products showing revenue growth [10][24] - Net revenue from Jornay PM reached $28.5 million in Q1 2025, with a year-over-year prescription growth of 24% [6][9] Strategic Initiatives - The company completed an expansion of its Jornay PM field force, adding 55 new sales representatives, bringing the total to approximately 180 [3][6] - Collegium reaffirmed its full-year 2025 guidance, projecting product revenues between $735 million and $750 million [8] - The board authorized a $25 million accelerated share repurchase program to enhance shareholder value [3][10] Cash Position and Debt Management - As of the end of Q1 2025, Collegium had cash, cash equivalents, and marketable securities totaling $197.8 million, an increase from $162.8 million at the end of 2024 [3][26] - The company paid down an additional $16.1 million in debt during the quarter [3][10] Leadership and Corporate Updates - Collegium made significant additions to its leadership team and board of directors, including the appointment of new executive leaders and board members [10][10] - The company was recognized as a Top Workplace by USA TODAY and a Best Places to Work honoree by the Boston Business Journal [10][10]

Core Insights - Genmab demonstrated significant progress in advancing its late-stage programs, with EPKINLY and Tivdak receiving approvals in additional territories, and Rina-S showing potential as a treatment for advanced ovarian cancer [2][7] Financial Performance - Genmab reported a revenue increase of 19% in Q1 2025, reaching $715 million compared to $603 million in Q1 2024, driven by higher royalties from DARZALEX and Kesimpta, as well as EPKINLY net product sales [7][8] - Royalty revenue rose to $589 million in Q1 2025, up 30% from $452 million in Q1 2024, attributed to increased net sales of DARZALEX and Kesimpta [8] - Net sales of DARZALEX reached $3,237 million in Q1 2025, a 20% increase from $2,692 million in Q1 2024 [8] - Total costs and operating expenses were $527 million in Q1 2025, an 8% increase from $487 million in Q1 2024, primarily due to product pipeline expansion and profit-sharing with AbbVie [8] - Operating profit for Q1 2025 was $188 million, compared to $116 million in Q1 2024 [8] - Net financial items resulted in income of $56 million in Q1 2025, down from $133 million in Q1 2024, mainly due to foreign exchange impacts from the change in functional currency [8] Outlook - Genmab is maintaining its 2025 financial guidance as published on February 12, 2025 [4] Other Matters - The functional currency of Genmab A/S has changed from DKK to USD effective January 1, 2025, with the presentation currency also changed to USD, affecting comparative figures for prior periods [5]

Core Viewpoint - Birchtech Corp. is set to release its financial results for the first quarter of 2025 on May 15, 2025, and will host an investor conference call to discuss these results and provide a corporate update [1][2]. Company Overview - Birchtech Corp. is a leader in specialty activated carbon technologies, focusing on sustainable air and water treatment solutions [4]. - The company offers patented SEA® sorbent technologies aimed at capturing mercury emissions in the coal-fired utility sector and is developing innovative water purification technologies targeting forever chemicals like PFAS and PFOS [4]. - Birchtech is recognized as America's clean coal and clean water company, committed to delivering cleaner air and water solutions [4]. Upcoming Events - The investor conference call is scheduled for May 15, 2025, at 5:00 p.m. Eastern time, with dial-in options provided for U.S./Canada and international participants [2]. - A telephone playback of the call will be available until June 13, 2025, along with a webcast replay accessible for one year [3].